The new-generation single-stroke reactors Nirsevimab were developed by Sanofi (France) and manufactured at a modern factory in the US. This is one of the "top-expected disease prevention weapons from both experts and parents to fight serious respiratory diseases in young children", said Dr. Bach Thi Chinh, Medical Director of the VNVC Vaccination System, at the launching ceremony on October 25.
Nirsevimab is produced using advanced recomboration technology, providing specific antibodies directly, helping the body create immunity right after vaccination instead of waiting 2-4 weeks for antibodies to regenerate themselves like the usual vaccine. This is the first RSV prevention solution to be researched and effectively applied to protect many groups of children, from pre-born children, children with underlying diseases to healthy children of many months, who account for the majority of hospitalizations due to RSV.
Children who only need a single dose of vaccination can reduce their risk of hospitalization and intensive treatment for RSV-related lower respiratory infections by more than 82% - including pneumonia, bronchitis, and maintain continuous protection for 5-6 months, equivalent to an RSV season. An antibodies can be injected immediately after birth, regardless of the maturity of the immune system, suitable for all infants. In particular, Nirsevimab is a single-stranded antibodies created from human cells, so it is highly safe and causes few reactions after injection.
As of October 2025, the Nirsevimab single-stroke antibodies have been approved in nearly 60 countries such as the US, France, UK, Canada, Japan, Australia, etc. and have been included in the national vaccination program in more than 25 developed countries. With many years of experience in the field of preventive vaccination and being a comprehensive strategic partner with Sanofi, VNVC and Tam Anh Hospital System brought single antibodies of the RSV vaccine line, helping Vietnam access the solution to prevent dangerous respiratory diseases caused by RSV early.
Associate Professor, Dr. Vu Huy Tru, Head of the Department of Pediatrics, Tam Anh General Hospital, Ho Chi Minh City, said that in Vietnam, RSVs operate all year round, often increasing sharply at the time of changing seasons, cold seasons and rainy seasons. The virus spreads through the respiratory tract, 4 times higher than the seasonal flu. The disease occurs at all ages and can appear very early in infants. Children with RSV are at risk of severe complications due to incomplete immune systems, narrow airways, easy blockage, and congestion.
Currently, RSV does not have a specific treatment, only to help relieve symptoms. Children with RSV bronchitis are very difficult to treat, not to mention that they can be infected with other diseases that increase the risk of serious illness. Many cases require ventilators, intensive treatment, which can easily lead to pulmonary fibrosis, impaired respiratory function, hospitalization or chronic bronchial asthma later.
Active direct immunotherapy for children with single-line antibodies, protecting children in the most susceptible and complicated stage of RSV from birth is a major turning point in reducing the rate of hospitalization, death and sequelae caused by RSV, saving resources, care costs for families, the health system and the whole society, Associate Professor Du assessed.
Currently, Tam Anh General Hospital System is implementing single-line antibodies vaccination at 5 hospitals and major medical examination and treatment centers in Hanoi and Ho Chi Minh City.
On the morning of October 25, Ms. Tuyet Hoa (An Phu Dong ward, Ho Chi Minh City) and her husband took their twin daughters to Tam Anh General Clinic District 7 for single-use RSV antibodies. The two children were born prematurely at week 33, and were given special care by doctors at the Neonatal Center, Tam Anh General Hospital, Ho Chi Minh City right after birth.
A 3-year-old baby was born prematurely at 25 weeks and was very susceptible to respiratory diseases because there were no RSV antibodies before. This time, as soon as Vietnam had a new generation of single-tone antibodies, my husband and I took our two children for vaccination, especially when RSV was in the peak season, said Ms. Hoa.
Previously, VNVC had deployed the first vaccination of RSV vaccine for people aged 60 and pregnant women from week 24-36, protecting mother and baby from the risk of RSV disease in the first 6 months of life.
The continued implementation of new solutions, proactively protecting young children right after birth affirms the pioneering role of the VNVC Vaccination System and the Tam Anh General Hospital System in striving to bring advanced biomedical technology achievements to Vietnam, contributing to the goal of high-tech health equality between Vietnam and developed countries, implementing the National Strategy for protecting, caring for and improving people's health, especially focusing on disease prevention.
